Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

類似資料

• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
  著者:: Sockel, Katja, 等
  出版事項: (2011)
• Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
  著者:: Schönefeldt, C, 等
  出版事項: (2013)
• Monitoring of donor chimerism in sorted CD34(+) peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
  著者:: Bornhäuser, Martin, 等
  出版事項: (2009)
• Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide
  著者:: Stölzel, Friedrich, 等
  出版事項: (2010)
• Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
  著者:: Oelschlaegel, U, 等
  出版事項: (2016)